The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Medibank (MPL) CEO Craig Drummond is stepping down from his role on June 30, marking the end of five years with the company
  • Before he departs, Drummond says the company will continue its focus on preventative healthcare, short stay programs, clinical homecare and access to virtual care
  • Medibank Chairman Mike Wilkins has praised Drummond for his tenure saying he’s leaving the company in a stronger position
  • Medibank Private shares are trading 3.36 per cent lower at $2.79

Medibank (MPL) CEO Craig Drummond is stepping down from his role on June 30, marking the end of five years with the company.

Before his departure, Drummond says the company will continue to focus on working to deliver more preventative healthcare, short stay programs, clinical homecare and access to virtual care, such as telehealth.

”Pleasingly, Medibank is on a clear strategic path to grow the private health insurance business at a faster rate and continue the transformation into a broader healthcare company,” Drummond said.

“’I could not have been blessed with a more competent executive leadership team or supportive board,” he continued.

Medibank Chairman Mike Wilkins praised Drummond for his contribution.

“Craig has done a wonderful job in leading and transforming Medibank. He will leave the company in a much stronger position, on a clear strategic path, with a great team. This is the mark of outstanding leadership,” Mike said.

Investors appear to be wary about the management shake-up, with Medibank shares closing  3.36 per cent lower at $2.79.

MPL by the numbers
More From The Market Online
The Market Online Video

Why Princeton Professor rates BlinkLab’s autism & ADHD screening app

In this interview with Sonia Madigan, Professor Sam Wang of Princeton University discusses the development and…

Orthocell’s Remplir shows 85% success rate in nerve repair study

Orthocell's medical device RemplirTM shows 85% success rate in latest nerve repair study, holding a promise…

ResMed spikes on robust results and global growth spurt

ResMed shares have climbed following the release of the company's strong Third Quarter FY2024 results.

PharmAust CEO’s sayanora triggers stock plunge

Clinical-stage biotechnology company, PharmAust shares plunged 24 per cent so this morning, following the resignation of…